Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.

about

Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.

Item

http://www.wikidata.org/entity/Q50889845

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Role for ZAP-70 Signaling in t ...... Lymphocytic Leukemia B Cells.

@en

Role for ZAP-70 Signaling in t ...... of Rituximab and Obinutuzumab

@nl

type

Item

label

Role for ZAP-70 Signaling in t ...... Lymphocytic Leukemia B Cells.

@en

Role for ZAP-70 Signaling in t ...... of Rituximab and Obinutuzumab

@nl

prefLabel

Role for ZAP-70 Signaling in t ...... Lymphocytic Leukemia B Cells.

@en

Role for ZAP-70 Signaling in t ...... of Rituximab and Obinutuzumab

@nl

P1476

Role for ZAP-70 Signaling in t ...... c Lymphocytic Leukemia B Cells

@en

P2093

Alexey V Danilov

http://www.w3.org/2001/XMLSchema#string

B JoNell Hamilton

http://www.w3.org/2001/XMLSchema#string

Jonathan D Jones

http://www.w3.org/2001/XMLSchema#string

William F C Rigby

http://www.w3.org/2001/XMLSchema#string

P2860

Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy

Dynamics of macrophage trogocytosis of rituximab-coated B cells

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.

P304

1275-1282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1602105

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

199

http://www.w3.org/2001/XMLSchema#string

P50

Sladjana Skopelja-Gardner

P577

2017-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28710251

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte